Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ME-344 in Early HER2-negative Breast Cancer
NCT02806817Phase 1Completed
- Sponsor
- Spanish National Cancer Research Centre
- Start
- Jul 2016
- Primary completion
- Oct 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ME-344 in breast cancer (2 arms), sponsored by Spanish National Cancer Research Centre. Primary endpoints: Reduction of FDG uptake at 1 month and SDH (succinate dehydrogenase) levels staining at 1 month. Started Jul 2016; status: completed.
02
Drugs
ME-344
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02806817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806817.